After launching the successful anti-COVID-19 & SARS-CoV S glycoprotein antibody clone CR3022, we are pleased to announce two anti-SARS-CoV-2 nucleoprotein (nucleocapsid) antibodies for COVID-19 research and diagnostics. Our recombinant antibody technology allows us to offer these antibodies in various engineered formats – such as human IgG1, IgG3, IgM and IgA; antibody fragments; and species such as rabbit and… Continue reading
